Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01794000 · ClinicalTrials.gov registry record · Phase 3
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 341
- Enrollment target
NCT01794000 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 341 participants.
The verdict
NCT01794000, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 341 participants
- Enrollment target
Study Summary
The main purpose of the study is to evaluate the efficacy and safety of the study drug known as prasugrel for the reduction of Vaso-Occlusive Crisis events in pediatric participants with sickle cell disease. The study will also investigate reduction in daily pain in children who have sickle cell disease.
Interventions
- DRUG Placebo
- DRUG Prasugrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 341 participants |
| Start Date | 2013-04 |
| Est. Completion | 2015-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01794000
The ClinicalTrials.gov registry entry for NCT01794000 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 341 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01794000 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01794000 about?
NCT01794000 is a clinical study titled "A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)". The main purpose of the study is to evaluate the efficacy and safety of the study drug known as prasugrel for the reduction of Vaso-Occlusive Crisis events in pediatric participants with sickle cell disease. The study will also investigate reduction in daily pain in children who have sickle cell dis...
What is the current status of trial NCT01794000?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 341 participants. The study started on 2013-04. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01794000?
The interventions under investigation include: Placebo (DRUG), Prasugrel (DRUG).
Who is sponsoring clinical trial NCT01794000?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.